A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination with Cemiplimab-rwlc (Libtayo ) in Subjects with Recurrent or Progressive Glioblastoma

Brief description of study

The purpose of this research study is to evaluate the safety and tolerability of intratumorally injected Ad-RTS-hIL-12 combined with oral veledimex, a viral gene therapy, in combination with cemiplimab-rwlc, a PD-1 inhibitor, in patients with recurrent glioblastoma.

Clinical Study Identifier: s19-00086
ClinicalTrials.gov Identifier: NCT04006119

If you are registered as a volunteer, please login to the dashboard to send referrals.